Chemours Co Form 8-K May 03, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

April 30, 2019

Date of Report (Date of Earliest Event Reported)

The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

| Delaware | 001-36794 | 46-4845564 |
|------------------------------|--------------|---------------------|
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| Of Incorporation) | File Number) | Identification No.) |

1007 Market Street

Wilmington, Delaware, 19899

(Address of principal executive offices)

Edgar Filing: Chemours Co - Form 8-K

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

| Title of Each Class | Trading Symbol(s) | Name of Exchange on Which Registered |
|--------------------------------|-------------------|--------------------------------------|
| Common Stock (\$.01 par value) | CC | New York Stock Exchange |

Item 5.07Submission of Matters to a Vote of Security Holders.

The Chemours Company held its annual meeting of shareholders on April 30, 2019 (the "Annual Meeting").

At the Annual Meeting, shareholders voted:

in favor of the election of all eight director nominees;in favor of the advisory "say-on-pay" vote;in favor of ratifying PricewaterhouseCoopers LLP; and against the shareholder proposal.

The final voting results were as follows:

Proposal 1 - Election of Directors to Serve One-Year Terms Expiring at the Annual Meeting of Shareholders in 2020

| Nominee | For | Against | Abstain Total | Broker Non-Votes |
|---------------------|-------------|------------|-----------------|------------------|
| | 128,495,71 | 3521,334 | 313,350129,330 |),39722,596,043 |
| Curtis V. Anastasio |) | | | |
| | (99.36%) | | | |
| | 127,559,27 | 31,460,772 | 2310,353129,330 |),39822,596,042 |
| Bradley J. Bell | | | | |
| | (98.63%) | | | |
| | 128,630,71 | 7381,990 | 317,691129,330 |),39822,596,042 |
| Richard H. Brown | | | | |
| | (99.46%) | | | |
| | 127,436,31 | 01,555,634 | 4338,458129,330 |),40222,596,038 |
| Mary B. Cranston | | | | |
| | (98.54%) | | | |
| | 126,524,66 | 52,489,39 | 9316,330129,330 |),39522,596,045 |
| Curtis J. Crawford | | | | |
| | (97.83%) | | | |
| | 127,605,954 | 41,416,17 | 6308,273129,330 |),40322,596,037 |
| Dawn L. Farrell | | | | |
| | (98.67%) | | | |
| Sean D. Keohane | 127,660,24 | 01,368,11 | 1302,052129,330 |),40322,596,037 |

Edgar Filing: Chemours Co - Form 8-K

(98.71%) 128,675,778339,681 314,939129,330,39822,596,042 Mark P. Vergnano (99.49%)

Proposal 2 - Advisory Vote to Approve Named Executive Officer Compensation

 For
 Against
 Abstain Total
 Broker Non-Votes

 122,836,7025,914,855578,827129,330,38422,596,056
 129,330,38422,596,056
 120,330,38422,596,056

(94.98%)

Proposal 3 - Ratification of Selection of PricewaterhouseCoopers LLP for Fiscal Year 2019

 For
 Against Abstain Total
 Broker Non-Votes

 150,960,667553,965411,808151,926,440 n/a

(99.36%)

Proposal 4 – Shareholder proposal for a report on executive compensation

For Against Abstain Total Broker Non-Votes 5,465,901122,015,1331,849,348129,330,38222,596,058

(4.23%)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY

By: /s/ Mark E. Newman Mark E. Newman Senior Vice President and Chief Financial Officer

Date: May 3, 2019